For patients on intermediate‐risk regimens, prophylactic use of G‐CSF is recommended if they meet certain conditions such as age > 65, prior chemotherapy or radiotherapy, bone marrow involvement, recent surgery and/or open wounds, persistent neutropenia, renal or liver dysfunction, or HIV infection [4]. Here, CSF3 is linked to Decreased total neutrophil count.